These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7779151

  • 21. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes.
    Büssing A, Stein GM, Pfüller U, Schietzel M.
    Anticancer Res; 1999; 19(3A):1785-90. PubMed ID: 10470116
    [Abstract] [Full Text] [Related]

  • 22. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems.
    Beuth J, Ko HL, Gabius HJ, Pulverer G.
    In Vivo; 1991; 5(1):29-32. PubMed ID: 1932621
    [Abstract] [Full Text] [Related]

  • 23. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
    Galanina OE, Kaltner H, Khraltsova LS, Bovin NV, Gabius HJ.
    J Mol Recognit; 1997; 10(3):139-47. PubMed ID: 9408830
    [Abstract] [Full Text] [Related]

  • 24. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
    Klein R, Classen K, Fischer S, Errenst M, Scheffler A, Stein GM, Scheer R, von Laue HB.
    Eur J Med Res; 2002 Aug 30; 7(8):359-67. PubMed ID: 12204844
    [Abstract] [Full Text] [Related]

  • 25. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
    Mengs U, Witthohn K, Schwarz T, Lentzen H.
    Wien Med Wochenschr; 1999 Aug 30; 149(8-10):262-4. PubMed ID: 10483695
    [Abstract] [Full Text] [Related]

  • 26. Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects.
    Huber R, Rostock M, Goedl R, Lüdtke R, Urech K, Klein R.
    J Soc Integr Oncol; 2006 Aug 30; 4(1):3-7. PubMed ID: 16737665
    [Abstract] [Full Text] [Related]

  • 27. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.
    Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Möckel B, Lentzen H, Gerstmayer B.
    Anticancer Res; 2001 Aug 30; 21(6A):3981-7. PubMed ID: 11911280
    [Abstract] [Full Text] [Related]

  • 28. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model.
    Elsässer-Beile U, Ruhnau T, Freudenberg N, Wetterauer U, Mengs U.
    Cancer; 2001 Mar 01; 91(5):998-1004. PubMed ID: 11251952
    [Abstract] [Full Text] [Related]

  • 29. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients.
    Hajto T, Hostanska K, Gabius HJ.
    Cancer Res; 1989 Sep 01; 49(17):4803-8. PubMed ID: 2758413
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients.
    Lenartz D, Stoffel B, Menzel J, Beuth J.
    Anticancer Res; 1996 Sep 01; 16(6B):3799-802. PubMed ID: 9042260
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mistletoe lectin-1 increases tumor necrosis factor-alpha release in lipopolysaccharide-stimulated whole blood via inhibition of interleukin-10 production.
    Boneberg EM, Hartung T.
    J Pharmacol Exp Ther; 2001 Sep 01; 298(3):996-1000. PubMed ID: 11504795
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
    Mengs U, Göthel D, Leng-Peschlow E.
    Anticancer Res; 2002 Sep 01; 22(3):1399-407. PubMed ID: 12168816
    [Abstract] [Full Text] [Related]

  • 37. Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy.
    Thies A, Pfüller U, Schachner M, Horny HP, Molls I, Schumacher U.
    Anticancer Res; 2001 Sep 01; 21(4B):2883-7. PubMed ID: 11712781
    [Abstract] [Full Text] [Related]

  • 38. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U.
    Anticancer Res; 2004 Sep 01; 24(2C):1293-302. PubMed ID: 15154663
    [Abstract] [Full Text] [Related]

  • 39. Clinical relevance of immunoactive mistletoe lectin-I.
    Beuth J.
    Anticancer Drugs; 1997 Apr 01; 8 Suppl 1():S53-5. PubMed ID: 9179369
    [Abstract] [Full Text] [Related]

  • 40. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients.
    Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K, Pulverer G.
    Clin Investig; 1992 Aug 01; 70(8):658-61. PubMed ID: 1392440
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.